Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: Available Pfizer-BioNTech Comirnaty product for children

Table 1. Comparison of the adult/youth and pediatric formulations of the Pfizer-BioNTech Comirnaty vaccine
Product specification Adult or adolescent formulation Pediatric formulationTable 1 Footnote a
Age 12 years of age and over 5-11 years
Vial Cap Color Purple Orange
Diluent (Only use 0.9% Sodium Chloride Injection, USP as the diluent) 1.8 mL 1.3 mL
Dose 0.3 mL (30 micrograms) 0.2 mL (10 micrograms)
Doses per vial 6 10
Potential allergens Polyethylene glycol (PEG) Polyethylene glycol (PEG) Tromethamine (Tris, Trometamol)Table 1 Footnote b
Post-dilution time
Can be at room temperature
6 hours 12 hours
Ancillary supplies Low dead volume needle/syringe Low dead volume needle/syringe
StorageTable 1 Footnote cTable 1 Footnote e
  • Ultra-frozen up to 6 months from the date of manufacture printed on the vial and cartonsTable 1 Footnote a
  • Do not store frozen in a regular freezer (not at -250C to -150C)
  • RefrigeratedTable 1 Footnote d for up to 10 weeks
  • Room temperatureTable 1 Footnote d for:
    • up to 12 hours prior to dilution;
    • up to 12 hours after dilution (i.e., post first puncture)
TransportTable 1 Footnote cTable 1 Footnote e
  • Ultra-frozen full cartons containing vials
  • RefrigeratedTable 1 Footnote d full cartons or individual undiluted vials. Transport time as required and in keeping with other storage requirements (up to 10 weeks).

Adapted from the National Advisory Committee on Immunization Recommendation on the use of Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age

References

Footnotes

Footnote 1

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age [Internet]. Silver Spring (MD): United States Food and Drug Administration; 2021 Oct 29 [cited 2021 Nov 12]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age

Return to footnote 1 referrer

Footnote 2

Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC. Vaccine allergy: evidence to consider for COVID-19 vaccines. Curr Opin Allergy Clin Immunol. 2021 Aug 1;214:401,409. doi: 10.1097/ACI.0000000000000762.

Return to footnote 2 referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: